Arvinas (NASDAQ:ARVN) Shares Down 7.8% – Here’s What Happened

Arvinas, Inc. (NASDAQ:ARVN)’s stock price was down 7.8% on Wednesday . The company traded as low as $11.16 and last traded at $11.0730. Approximately 142,314 shares traded hands during mid-day trading, a decline of 82% from the average daily volume of 785,898 shares. The stock had previously closed at $12.01.

More Arvinas News

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Positive Phase 1 data for ARV-102 showed >50% LRRK2 degradation in CSF after 28 days and reductions in endolysosomal and neuroinflammatory biomarkers—data that de‑risks the Parkinson’s program and increases the drug’s clinical value. Arvinas Announces Positive Phase 1 Data for ARV-102
• Positive Sentiment: Citigroup raised its price target from $18 to $21 and initiated/maintained a Buy rating—an analyst upgrade that implies a large upside and can attract momentum investors. Benzinga
• Positive Sentiment: BTIG bumped its target from $14 to $16 and keeps a Buy rating, providing additional brokerage support for the shares and reinforcing the sentiment shift after the clinical news. Benzinga
• Neutral Sentiment: Short-interest reports for mid‑March show anomalous zero/NaN values and a 0.0 days-to-cover figure—data appears unreliable or miscoded and currently offers no clear sign of increased short pressure. Investors should watch for corrected filings for a clearer picture. TipRanks / Short Interest Note

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ARVN shares. Wedbush upped their target price on shares of Arvinas from $9.00 to $11.00 and gave the company a “neutral” rating in a research note on Tuesday, February 24th. Truist Financial set a $10.00 price target on shares of Arvinas in a report on Wednesday. BTIG Research raised their price objective on Arvinas from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday. Barclays lifted their target price on Arvinas from $16.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Arvinas in a research note on Monday, December 22nd. Ten equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $13.88.

Arvinas Stock Performance

The firm has a market capitalization of $714.43 million, a P/E ratio of -8.73 and a beta of 1.87. The firm’s 50-day moving average is $12.72 and its 200 day moving average is $11.13.

Arvinas (NASDAQ:ARVN) last released its earnings results on Tuesday, February 24th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.55). The firm had revenue of $9.50 million for the quarter, compared to the consensus estimate of $37.26 million. Arvinas had a negative return on equity of 14.25% and a negative net margin of 30.77%.Arvinas’s revenue for the quarter was down 84.0% on a year-over-year basis. During the same quarter last year, the company posted ($0.63) EPS. As a group, research analysts expect that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Insider Buying and Selling at Arvinas

In other news, Director Briggs Morrison bought 20,000 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The shares were acquired at an average price of $13.40 per share, with a total value of $268,000.00. Following the transaction, the director owned 96,021 shares in the company, valued at $1,286,681.40. This represents a 26.31% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director John G. Houston sold 35,297 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $13.21, for a total value of $466,273.37. Following the completion of the sale, the director owned 1,122,183 shares in the company, valued at $14,824,037.43. The trade was a 3.05% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 63,864 shares of company stock valued at $802,443 in the last 90 days. 4.73% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Corient Private Wealth LLC bought a new stake in Arvinas during the 4th quarter worth about $127,000. Invesco Ltd. increased its position in shares of Arvinas by 26.9% in the fourth quarter. Invesco Ltd. now owns 302,100 shares of the company’s stock valued at $3,583,000 after acquiring an additional 64,044 shares during the last quarter. State of Tennessee Department of Treasury acquired a new stake in shares of Arvinas in the fourth quarter valued at about $323,000. Ikarian Capital LLC increased its position in shares of Arvinas by 58.3% in the fourth quarter. Ikarian Capital LLC now owns 358,257 shares of the company’s stock valued at $4,249,000 after acquiring an additional 132,000 shares during the last quarter. Finally, Voloridge Investment Management LLC bought a new stake in Arvinas during the fourth quarter worth about $1,079,000. Institutional investors and hedge funds own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.